24 records found.
Feb 14, 2019
Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)
Feb 05, 2019
Bayer to Showcase New Data from its Growing Cancer Portfolio at 2019 ASCO GU Cancers Symposium
Nov 28, 2018
NextGen Skeletal Cancer Drug Therapies Aim at Combating the Rising Incidence Rate of Global Cancer
Sep 11, 2018
Health-Related Quality of Life Maintained with Addition of ERLEADA® to Androgen Deprivation Therapy for Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Sep 10, 2018
Global Metastatic Bone Disease Market 2017-2023
Aug 20, 2018
Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain
Jul 04, 2018
Health Canada Approves ERLEADA(TM)* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer
Jul 02, 2018
Metastatic Bone Disease Market to Gain US$ 24,886.8 Mn by 2026, Says TMR
May 31, 2018
Bayer Partners with U.S. Department of Energy to Produce Key Starting Material for Xofigo® (radium Ra 223 dichloride) Injection
May 18, 2018
ERLEADA(TM) Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Mar 16, 2018
Significant Progress in Non-opioid Therapy Picks up Steam as Market Projected to Reach $22 Billion by 2022
Mar 16, 2018
Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain
Feb 14, 2018
ERLEADA(TM) (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 08, 2018
ERLEADA(TM) (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 07, 2018
Bayer to Feature Prostate Cancer Research at ASCO GU 2018 Symposium
Jan 24, 2018
Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Dec 21, 2017
Q BioMed Provides Year End Update
Dec 14, 2017
Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer
Oct 05, 2017
Q BioMed Announces Launch of PainFreeCancer.com Website in Support of Non-Opioid Cancer Pain Drug
Aug 22, 2017
New Data on High Dose Vitamin C Therapy and Prostate Cancer

Pages